Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M5,031Revenue $M1,054Net Margin (%)0.8Z-Score2.4
Enterprise Value $M6,096EPS $-0.3Operating Margin %5.3F-Score3
P/E(ttm))3,503Cash Flow Per Share $2.2Pre-tax Margin (%)-2.4Higher ROA y-yN
Price/Book3.410-y EBITDA Growth Rate %0Quick Ratio2.7Cash flow > EarningsY
Price/Sales4.65-y EBITDA Growth Rate %-24.1Current Ratio2.8Lower Leverage y-yN
Price/Cash Flow18.6y-y EBITDA Growth Rate %-57.3ROA % (ttm)0.3Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)0.6Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M75.3ROI % (ttm)5.6Gross Margin Increase y-yN

Gurus Latest Trades with CBST

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CBSTLee Ainslie 2014-06-30 Sold Out -1.8%$61.66 - $74.27
($67.99)
$ 66.67-2%Sold Out0
CBSTGeorge Soros 2014-06-30 Sold Out -0.04%$61.66 - $74.27
($67.99)
$ 66.67-2%Sold Out0
CBSTLee Ainslie 2014-03-31 Buy 1.8%$67.2 - $81.23
($74.39)
$ 66.67-10%New holding, 1739818 sh.1,739,818
CBSTGeorge Soros 2014-03-31 Reduce-0.06%$67.2 - $81.23
($74.39)
$ 66.67-10%Reduce -65.4%50,000
CBSTJohn Burbank 2013-12-31 Sold Out -0.42%$61.59 - $70.76
($64.66)
$ 66.673%Sold Out0
CBSTJoel Greenblatt 2013-12-31 Sold Out -0.05%$61.59 - $70.76
($64.66)
$ 66.673%Sold Out0
CBSTJohn Burbank 2013-09-30 Buy 0.42%$51.58 - $66.54
($60.56)
$ 66.6710%New holding, 202451 sh.202,451
CBSTMichael Price 2013-09-30 Sold Out -1.2%$51.58 - $66.54
($60.56)
$ 66.6710%Sold Out0
CBSTGeorge Soros 2013-06-30 Buy 0.09%$44.66 - $56.11
($49.15)
$ 66.6736%New holding, 175000 sh.175,000
CBSTJohn Hussman 2013-03-31 Sold Out -0.75%$40.78 - $48.06
($44.18)
$ 66.6751%Sold Out0
CBSTJoel Greenblatt 2013-03-31 Reduce-0.18%$40.78 - $48.06
($44.18)
$ 66.6751%Reduce -72.24%28,134
CBSTJoel Greenblatt 2012-12-31 Buy 0.25%$39.17 - $48.63
($43.07)
$ 66.6755%New holding, 101334 sh.101,334
CBSTJoel Greenblatt 2012-09-30 Sold Out -0.12%$37.91 - $49.83
($43.89)
$ 66.6752%Sold Out0
CBSTJoel Greenblatt 2012-06-30 Add0.04%$38.38 - $44.07
($40.88)
$ 66.6763%Add 49.02%41,492
CBSTJohn Hussman 2012-03-31 Add0.18%$38.77 - $44.72
($38.64)
$ 66.6772%Add 47.16%674,000
CBSTJoel Greenblatt 2012-03-31 Reduce-0.17%$38.77 - $44.72
($38.64)
$ 66.6772%Reduce -55.29%27,844
CBSTGeorge Soros 2012-03-31 Sold Out -0.09%$38.77 - $44.72
($38.64)
$ 66.6772%Sold Out0
CBSTJohn Hussman 2011-12-31 Add0.26%$34.05 - $40.38
($37.51)
$ 66.6778%Add 798.04%458,000
CBSTJoel Greenblatt 2011-12-31 Reduce-0.42%$34.05 - $40.38
($37.51)
$ 66.6778%Reduce -53.85%62,273
CBSTGeorge Soros 2011-12-31 Reduce-0.03%$34.05 - $40.38
($37.51)
$ 66.6778%Reduce -50%50,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CBST is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
CBST Vanguard Health Care Fund 2014-06-301,467,5421.950.27+10.91%
CBST George Soros 2014-06-30000Sold Out
CBST Lee Ainslie 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


CBST: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
STEA GREGORYSVP, Commercial Operations 2014-08-19Sell38,326$65.881.2view
TOMSICEK MICHAEL JOHNSVP & CFO 2014-08-18Sell409$63.684.7view
PEREZ ROBERT JPresident & COO 2014-08-18Sell1,003$63.684.7view
Hutson Nancy JDirector 2014-08-18Sell9,000$652.57view
GILMAN STEVEN CEVP & Chief Scientific Officer 2014-07-28Sell40,625$61.578.28view
STEA GREGORYSVP, Commercial Operations 2014-05-15Sell875$67.5-1.23view
PEREZ ROBERT JPresident & COO 2014-05-15Sell1,518$67.5-1.23view
GILMAN STEVEN CEVP & Chief Scientific Officer 2014-05-15Sell16,340$67.82-1.7view
BONNEY MICHAEL WCEO 2014-05-15Sell3,036$67.5-1.23view
BONNEY MICHAEL WCEO 2014-05-14Sell3,840$69-3.38view

Press Releases about CBST :

    Quarterly/Annual Reports about CBST:

    News about CBST:

    Articles On GuruFocus.com
    Forest Laboratories Is an Option for Wealthy Investors Who Could Afford to Pay a High Premium Apr 23 2014 
    Michael Price’s Top Sells – 11 Gurus Exit SFD Nov 19 2013 
    Magic Formula Formulator Joel Greenblatt’s Top 5 New Stock Picks Feb 14 2013 
    5 Healthcare Stocks to Consider in 2012 Mar 21 2012 
    Cubist Pharmaceutical - Acutely Aware May 09 2010 
    Cubist Pharmaceutical - Acutely Aware May 09 2010 
    Cubist Pharmaceuticals Inc. Reports Operating Results (10-Q) Apr 29 2010 
    Weekly CEO Sells Highlight: Saba Software Inc, Cubist Pharmaceuticals Inc, Polo Ralph Lauren Corp, P Apr 25 2010 
    Cubist Pharmaceuticals Inc. (CBST) President and CEO Michael W Bonney sells 184,548 Shares Apr 23 2010 
    Cubist Pharmaceuticals: A Drug Stock With Potential For Solid Gain Feb 15 2010 

    More From Other Websites
    White House calls for task force to tackle antibiotic-resistant bugs Sep 18 2014
    Cubist Announces Continued Global Expansion with Opening of International Headquarters in Zurich Sep 18 2014
    Cubist to Present New Data from Antibiotics Portfolio at 54th Interscience Conference on... Aug 26 2014
    Cubist Pharmaceuticals' Antibiotic Accepted for EU Review Aug 25 2014
    Cubist to Present at Morgan Stanley Global Healthcare Conference Aug 25 2014
    Cubist Announces EMA Acceptance of Ceftolozane/Tazobactam Marketing Authorization Application for... Aug 22 2014
    Cubist Pharmaceuticals (CBST) Marked As A Barbarian At The Gate Aug 18 2014
    Cubist Battling Superbugs Offers Remedy for J&J: Real M&A Aug 18 2014
    Extreme medicine: The search for new antibiotics Aug 18 2014
    Extreme medicine: The search for new antibiotics Aug 17 2014
    Extreme medicine: The search for new antibiotics Aug 17 2014
    CUBIST PHARMACEUTICALS INC Financials Aug 15 2014
    CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Financial Statements and Exhibits Aug 11 2014
    CUBIST PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 11 2014
    Cubist Pharmaceuticals Issues Voluntary Nationwide Recall of Nine Lots of CUBICIN (daptomycin for... Aug 08 2014
    Is Durata's Antibiotic Overpriced? A Twitter Conversation Aug 07 2014
    Cubist recalls antibiotic over possible glass Aug 06 2014
    Cubist recalls antibiotic over possible glass Aug 06 2014
    Cubist Pharmaceuticals Issues Voluntary U.S. Recall of Certain Lots of CUBICIN (daptomycin for... Aug 06 2014
    Cubist Pharma recalls some vials of antibiotic Cubicin Aug 06 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK